Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Blue Water Life Science Advisors, LP

Q4 2023 · 13F-HR

Blue Water Life Science Advisors, LPholdings as filed

Filed 2024-02-14 · accession 0001172661-24-001487

$114.2M
Reported value
9
Positions
2023-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
632307104NTRANATERA INC$24.9M21.8%397,436CommonSOLE
00974H104AKOYA BIOSCIENCES INC$22.9M20.1%4,697,785CommonSOLE
40131M109GHGUARDANT HEALTH INC$15.4M13.5%571,047CommonSOLE
883556102TMOTHERMO FISHER SCIENTIFIC INC$13.7M12.0%25,800CommonSOLE
88025U109TXG10X GENOMICS INC$10.9M9.53%194,500CommonSOLE
57777K106MXCTMAXCYTE INC$8.9M7.76%1,885,000CommonSOLE
00650F109ADPTADAPTIVE BIOTECHNOLOGIES COR$8.3M7.24%1,687,665CommonSOLE
74766Q101QTRXQUANTERIX CORP$7.9M6.90%288,196CommonSOLE
63009R109NSTGEURNANOSTRING TECHNOLOGIES INC$1.3M1.15%1,751,891CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.